Welcome to our dedicated page for Xtant Medical news (Ticker: XTNT), a resource for investors and traders seeking the latest updates and insights on Xtant Medical stock.
Xtant Medical Holdings, Inc. (XTNT) is a leader in regenerative medicine, specializing in orthobiologics and spinal implant systems for complex surgical procedures. This page aggregates official company news, including product developments, financial updates, and strategic initiatives within the orthopedic and neurological sectors.
Investors and healthcare professionals will find verified press releases covering regulatory milestones, partnership announcements, and advancements in bone healing technologies. Our repository ensures access to timely updates on Xtant Medical's surgical solutions, including spinal fusion devices and biologics designed to improve patient outcomes.
Bookmark this page for direct access to earnings reports, acquisition news, and clinical trial progress. All content is sourced from official channels to maintain accuracy and compliance with financial disclosure standards.
Xtant Medical Holdings (NYSE American: XTNT) will announce its Q1 2023 financial results on May 4, 2023, before market open. A conference call will follow at 9:00 AM ET, led by CEO Sean Browne and CFO Scott Neils, to discuss the results. Interested parties can join through dial-in numbers or via a webcast registration link provided in the release. Xtant Medical specializes in medical technology, focusing on orthobiologics and spinal implant systems for spinal fusion procedures. The company emphasizes integrity and dedication in serving its customers. For further information, a replay of the call will be accessible on the company's website after the live event.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) reported strong fourth quarter and full year 2022 financial results, with revenues growing 9% to $15.3 million for Q4 and 5% to $58.0 million for the full year. The company's biologics products drove a 14% revenue increase in Q4. Despite a decline in gross margin to 54.4% due to higher production costs, the acquisition of the Coflex® product line enhances its offerings. The net loss for 2022 increased to $8.5 million, or $0.09 per share, signaling challenges despite revenue growth. A conference call is scheduled to discuss these results further.
Xtant Medical Holdings, Inc. (NYSE American: XTNT) is set to release its financial results for the fourth quarter and full year ended December 31, 2022, before the market opens on March 7, 2023. The results will be discussed in a conference call hosted by CEO Sean Browne and CFO Scott Neils at 9:00 AM ET on the same day. Investors can participate by calling 877-407-6184 or registering for the webcast on the company’s website. Xtant specializes in surgical solutions for spinal disorders, focusing on orthobiologics and spinal implant systems designed to facilitate spinal fusion.
FAQ
What is the current stock price of Xtant Medical (XTNT)?
What is the market cap of Xtant Medical (XTNT)?
